Demographic Data |
Demographic Data |
Demographic Data |
Demographic
Data |
Demographic Data |
Age (years), mean ± SD |
67 ± 9 |
67 ± 9 |
65 ± 9 |
0.589 |
Male gender, n (%) |
37 (79) |
37 (79) |
32 (76) |
0.775 |
Heart failure condition |
Heart failure condition |
Heart failure
condition |
Heart failure condition |
Heart failure
condition |
Ischemic heart failure, n (%) |
23(49) |
23(49) |
24 (57) |
0.439 |
LV ejection fraction (%), mean ± SD |
27 ± 7 |
27 ± 7 |
28 ± 6 |
0.152 |
NHYA class I-II, n (%) |
38 (81) |
38 (81) |
32 (76) |
0.250 |
Risk factors and history |
Risk factors and history |
Risk factors and
history |
Risk factors and history |
Risk factors and
history |
Hypertension, n (%) |
30 (64) |
30 (64) |
32 (76) |
0.205 |
Diabetes mellitus, n (%) |
16 (34) |
16 (34) |
20 (48) |
0.193 |
Smoking1, n (%) |
17 (36) |
17 (36) |
13 (31) |
0.326 |
Dyslipidemia, n (%) |
29 (62) |
29 (62) |
26 (62) |
0.984 |
Lung disease2, n (%) |
6 (13) |
6 (13) |
10 (11) |
0.554 |
Obstructive Sleep Apnea, n (%) |
9 (19) |
9 (19) |
2 (5) |
0.040 |
Stroke/transient ischemic attack, n (%) |
3 (6) |
3 (6) |
9 (21) |
0.038 |
Atrial fibrillation (AF) |
16 (34) |
16 (34) |
18 (43) |
0.393 |
Medication |
Medication |
Medication |
Medication |
Medication |
ACEI/ARB/ARNI, n (%) |
45 (96) |
45 (96) |
40 (95) |
0.908 |
Beta-blocker, n (%) |
42 (89) |
42 (89) |
39 (93) |
0.565 |
Aldosterone antagosnists, n (%) |
28 (60) |
28 (60) |
21 (50) |
0.365 |
Diuretic, n (%) |
33 (70) |
33 (70) |
33 (79) |
0.369 |
Digoxin, n (%) |
4 (9) |
4 (9) |
4 (10) |
0.868 |
Anti-arrhytmic drugs3, n (%) |
6 (13) |
6 (13) |
3
(7) |
0.380 |
Oral anticoagulation, n (%) |
23 (49) |
23 (49) |
20 (48) |
0.901 |
Type of device |
Type of device |
Type of device |
Type of device |
Type
of device |
Implantable cardioverter-defibrillator, n (%) |
26 (55) |
26 (55) |
21
(50) |
0.616 |